Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

February 26, 2024

Study Completion Date

February 26, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

Lutikizumab Dose A

Injection; subcutaneous (SC)

DRUG

Lutikizumab Dose B

Injection; subcutaneous (SC)

Trial Locations (3)

Acpru /Id# 259029, Grayslake

PPD Clinical Research Unit - Austin /ID# 260141, Austin

Altasciences Clinical Los Angeles, Inc /ID# 260986, Cypress